Moderna, a clinical stage biotechnology company, focuses on the research and development of messenger RNA therapeutics and vaccines. The company develops mRNA medicines for immuno-oncology, infectious, and cardiovascular diseases.
The COVID-19 vaccine made the biotechnology company Moderna cash-positive. Moderna has the broadest R&D pipeline within the scope of mRNA. The company’s most advanced program is the approved COVID-19 vaccine to turn cells into vaccine factories. Further clinical candidates are passing through trials as vaccines for virus infections or as therapeutics in immuno-oncology. The biotechnology company has currently 24 development candidates, eight of which are infectious disease-focused clinical candidates in its pipeline.
Its COVID-19 vaccine is 94.1% effective across all age groups, according to clinical trials. The high probability of response is a crucial factor because the human mRNA has the identical chemical structure in all molecules, and mRNA-based medicines differ only in the coded genetic information they comprise.
Other companies using mRNA technology for developing COVID-19 vaccines include but are not limited to Germany’s BioNTech and CureVac. Messenger RNA, or mRNA, transfers the instructions stored in DNA to make the proteins vitally needed in every living cell. The innovative approach is to apply mRNA medicines to instruct a patient’s own cells to make proteins that patients are unable to produce themselves. These proteins could prevent, treat, or cure disease.
Moderna was initially focused on drugs. In 2017 the company started developing vaccines for several viruses like MERS. Beyond BioNTech started working on infectious disease in 2018 while developing a vaccine for seasonal flu in cooperation with Pfizer. Previously it was focused on cancer drugs. Moderna’s stock price climbed as much as 395% within one year. BioNTech’s stocks increased 193% in the same period.